The “Mantle Cell Lymphoma Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029” report has been added to ResearchAndMarkets.com’s offering.
The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possesses an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib, and KTE-C19.
To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of the mechanism of action are Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Prnewswire
